文献速递消化系统肿瘤

理解原发肿瘤部位在结直肠癌治疗与结局中的作用

Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes.
PubMed 文献 · Eur J Cancer · 2017-08-05

转移性结直肠癌(mCRC)是一种异质性疾病,结局和临床反应各异且预后差。结直肠癌可按原发肿瘤在结肠内的位置进行表征:左半结肠起源于后肠,包括横结肠远端三分之一、脾曲、降结肠、乙状结肠和直肠;右半结肠起源于中肠,包括横结肠近端三分之二、升结肠和盲肠。有时直肠虽起源于后肠却被单独描述,且在许多临床系列中左半结肠仅包括脾曲及其远端肿瘤。无论定义如何,右半结肠与左半结肠之间在微生物组、临床特征及染色体和分子特征方面均存在差异。目前来自mCRC患者临床研究的强证据支持原发肿瘤部位的预后效应,而原发结肠肿瘤部位对治疗反应的影响正于大量mCRC临床研究中接受考察。本综述总结了与结直肠癌原发部位相关的微生物组、临床、染色体和分子差异,概述了原发肿瘤部位对mCRC患者预后影响的已证实证据,并讨论了原发肿瘤部位对临床结局预测影响的新兴数据。

要点

  • 左半结肠包括横结肠远端三分之一、脾曲、降结肠、乙状结肠和直肠;右半结肠包括横结肠近端三分之二、升结肠和盲肠。
  • 右半与左半结肠在微生物组、临床特征及染色体和分子特征方面存在差异,且不取决于定义方式。
  • mCRC患者临床研究的强证据支持原发肿瘤部位的预后效应,其对治疗反应的预测影响正在研究中。

核心结论

  • 来自mCRC患者临床研究的强证据支持原发肿瘤部位的预后效应。
  • 原发结肠肿瘤部位对治疗反应的影响正于大量mCRC临床研究中接受考察。

研究设计与样本

  • 综述,总结与结直肠癌原发部位相关的微生物组、临床、染色体和分子差异,并概述原发肿瘤部位对mCRC患者预后影响的已证实证据及对临床结局预测影响的新兴数据。

主要发现

  • 右半与左半结肠之间在微生物组、临床特征及染色体和分子特征方面存在差异,且不取决于定义方式。
  • 来自mCRC患者临床研究的强证据支持原发肿瘤部位的预后效应。
  • 原发结肠肿瘤部位对治疗反应的影响正于大量mCRC临床研究中接受考察。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metastatic colorectal carcinoma (mCRC) is a heterogeneous disease with differing outcomes and clinical responses and poor prognosis. CRCs can be characterised by their primary tumour location within the colon. The left-sided colon, derived from the hindgut, includes the distal third of the transverse colon, splenic flexure, descending colon, sigmoid colon and rectum. The right-sided colon, derived from the midgut, includes the proximal two-thirds of the transverse colon, ascending colon and caecum. Sometimes, the rectum is described separately, despite originating from the hindgut, and in many clinical series, the left-sided colon includes only tumours within and distal to the splenic flexure. Differences in the microbiome, clinical characteristics and chromosomal and molecular characteristics have been reported between the right and left side of the colon, regardless of how this is defined. There is now strong evidence from clinical studies in patients with mCRC for the prognostic effect of primary tumour location. The impact of primary colonic tumour location on response to treatment is now under investigation in a large number of clinical studies in patients with mCRC. In this review, we summarise the microbiome, clinical, chromosomal and molecular differences associated with the primary location of CRC. We present an overview of the proven prognostic impact of primary tumour location for patients with mCRC and discuss emerging data for the predictive impact of primary tumour location on clinical outcome.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Stintzing S, Tejpar S, Gibbs P, et al. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. Eur J Cancer. 2017. PMID: 28787661. doi:10.1016/j.ejca.2017.07.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。